American Medical Systems Holdings Inc (GB) SEC Filing 10-K Annual report for the fiscal year ending Saturday, January 1, 2011

Exhibit 99.1

DATE: February 15, 2011

FOR IMMEDIATE RELEASE

AMERICAN MEDICAL SYSTEMS CONFIRMS FOURTH QUARTER REVENUE AND FINISHES 2010 WITH STRONG FINANCIAL PERFORMANCE

	•		Fourth quarter revenue of $147.0 million grows 0.7%; 4.0% growth excluding impact of currency and previously divested Uterine Health product line
	•		Fourth quarter non-GAAP adjusted EPS of $0.40 grows 14.3% over prior year; GAAP EPS of $0.35 grows 16.7% over prior year
	•		Continued strong cash generation drives retirement of senior secured debt in the fourth quarter

MINNEAPOLIS, February 15, 2011 — American Medical Systems Holdings, Inc. (NASDAQ: AMMD) confirmed previously reported revenue of $147.0 million for the fourth quarter of 2010, a 0.7 percent increase over sales of $146.0 million in the comparable quarter of 2009. Adjusting for the negative impact of the stronger U.S. dollar in the fourth quarter of 2010 results in growth of 1.7 percent over the same quarter last year. Further adjusting revenue for the impact of the Her Option® uterine health product line, which was sold during the first quarter of 2010, results in constant currency revenue growth of 4.0 percent. Full year 2010 revenue of $542.3 million grew 4.4 percent over 2009 revenue of $519.3 million. Adjusting for the impact of foreign currency fluctuations, which was negative $0.1 million, and the impact of the Her Option® uterine health product line divestiture results in 2010 constant currency revenue growth of 5.9% over 2009.

Men’s Health sales of $65.2 million in the fourth quarter represented an increase of 2.7 percent on a reported basis compared to the same quarter last year, and grew 4.1 percent on a constant currency basis, with growth in the erectile restoration and male continence product lines roughly equal. The BPH Therapy business declined 2.1 percent on a reported basis and 1.0 percent on a constant currency basis to $32.6 million for the quarter. BPH Therapy sales were led by an enthusiastic response to the new GreenLight™ XPS console, offset by a decline in fiber sales due to limited availability of the recently launched MoXy™ Liquid Cooled Fiber and challenging international markets. The Women’s Health business increased 6.7 percent on a reported basis and 7.4 percent on a constant currency basis to $48.8 million in the fourth quarter. The female continence product line benefited from the recent introduction of the MiniArc® Precise Single-Incision Sling System for the treatment of female stress urinary incontinence, and the pelvic floor repair product line continued its strong performance driven by the success of both the Elevate® anterior and posterior systems.

The Company reported fourth quarter net income of $27.2 million, or $0.35 per share. This compares to net income in the same quarter last year of $22.3 million, or $0.30 per share, a growth of 16.7 percent. Non-GAAP adjusted earnings per share of $0.40 compares to $0.35 per share in the same quarter last year, a growth of 14.3 percent, finishing two cents above the top of guidance for the quarter. Full year 2010 net income of $87.0 million, or $1.12 per share, compares to full year 2009 income of $84.8 million, or $1.14 per share, a decline of 1.8 percent. Non-GAAP adjusted earnings per share for 2010 of $1.30 grew 12.1 percent over 2009 non-GAAP adjusted earnings per share of $1.16. Non-GAAP adjusted earnings per share excludes the